Our findings demonstrate that inhibition of collagen deposition by targeting LOXL2 can overcome anti-PD-(L)1 resistance by increasing the infiltration and activation state of intratumoral CD8+ T cells in multiple syngeneic models of lung cancer. Here, LOXL2 is linked to lung cancer.